KR20050067384A - 부분적 또는 완전한 a1 아데노신 수용체의 작용제 - Google Patents

부분적 또는 완전한 a1 아데노신 수용체의 작용제 Download PDF

Info

Publication number
KR20050067384A
KR20050067384A KR1020057002587A KR20057002587A KR20050067384A KR 20050067384 A KR20050067384 A KR 20050067384A KR 1020057002587 A KR1020057002587 A KR 1020057002587A KR 20057002587 A KR20057002587 A KR 20057002587A KR 20050067384 A KR20050067384 A KR 20050067384A
Authority
KR
South Korea
Prior art keywords
purin
compound
formula
optionally substituted
diol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057002587A
Other languages
English (en)
Korean (ko)
Inventor
제프 자블록키
벤카타 팔레
엘파티 엘제인
샤오펀 리
Original Assignee
씨브이 쎄러퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨브이 쎄러퓨틱스, 인코포레이티드 filed Critical 씨브이 쎄러퓨틱스, 인코포레이티드
Publication of KR20050067384A publication Critical patent/KR20050067384A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020057002587A 2002-08-15 2003-08-15 부분적 또는 완전한 a1 아데노신 수용체의 작용제 Ceased KR20050067384A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40371202P 2002-08-15 2002-08-15
US60/403,712 2002-08-15
US45009403P 2003-02-25 2003-02-25
US60/450,094 2003-02-25

Publications (1)

Publication Number Publication Date
KR20050067384A true KR20050067384A (ko) 2005-07-01

Family

ID=31891396

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057002587A Ceased KR20050067384A (ko) 2002-08-15 2003-08-15 부분적 또는 완전한 a1 아데노신 수용체의 작용제

Country Status (15)

Country Link
US (2) US7022681B2 (cg-RX-API-DMAC7.html)
EP (1) EP1537133B1 (cg-RX-API-DMAC7.html)
JP (1) JP4596913B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050067384A (cg-RX-API-DMAC7.html)
CN (1) CN100480255C (cg-RX-API-DMAC7.html)
AT (1) ATE368048T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003263846B2 (cg-RX-API-DMAC7.html)
CA (1) CA2495370A1 (cg-RX-API-DMAC7.html)
DE (1) DE60315164T2 (cg-RX-API-DMAC7.html)
ES (1) ES2288632T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05001844A (cg-RX-API-DMAC7.html)
NO (1) NO20051296L (cg-RX-API-DMAC7.html)
NZ (1) NZ538590A (cg-RX-API-DMAC7.html)
RU (1) RU2340623C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004016635A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636229A4 (en) 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
KR20140041965A (ko) * 2007-05-17 2014-04-04 씨브이 쎄러퓨틱스, 인코포레이티드 A2a-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
US20140357594A1 (en) * 2011-10-24 2014-12-04 Glaxosmithkline Intellectual Property (No.2) Limited New compounds
EA031895B1 (ru) * 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
JP6643719B2 (ja) * 2016-05-31 2020-02-12 セントラル硝子株式会社 3,3,3−トリフルオロプロパノールの製造方法
CN115232054A (zh) * 2021-04-22 2022-10-25 山东新时代药业有限公司 一种7-乙基色醇中间体化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1254888A (en) * 1984-10-26 1989-05-30 Bharat Trivedi N.sup.6-bicycloadenosines
USRE36494E (en) * 1990-02-20 2000-01-11 Discovery Therapeutics, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5140015A (en) * 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5278150A (en) * 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5589467A (en) * 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
AU4377397A (en) * 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US20040162422A1 (en) 2001-03-20 2004-08-19 Adrian Hall Chemical compounds

Also Published As

Publication number Publication date
JP4596913B2 (ja) 2010-12-15
NZ538590A (en) 2006-10-27
EP1537133B1 (en) 2007-07-25
RU2005106997A (ru) 2005-11-10
CA2495370A1 (en) 2004-02-26
US20060135467A1 (en) 2006-06-22
MXPA05001844A (es) 2005-04-19
WO2004016635A3 (en) 2004-04-08
WO2004016635A2 (en) 2004-02-26
DE60315164T2 (de) 2008-04-30
ATE368048T1 (de) 2007-08-15
DE60315164D1 (de) 2007-09-06
ES2288632T3 (es) 2008-01-16
RU2340623C2 (ru) 2008-12-10
US20040043960A1 (en) 2004-03-04
AU2003263846A1 (en) 2004-03-03
CN1675235A (zh) 2005-09-28
AU2003263846B2 (en) 2009-12-17
JP2006505525A (ja) 2006-02-16
EP1537133A2 (en) 2005-06-08
NO20051296L (no) 2005-05-13
US7022681B2 (en) 2006-04-04
CN100480255C (zh) 2009-04-22

Similar Documents

Publication Publication Date Title
AU2008249143B2 (en) Partial and full agonists of A1 adenosine receptors
JP2010513565A (ja) A1アデノシン受容体の部分アゴニストまたは完全アゴニストとしてのアデノシン誘導体
US7271157B2 (en) A1 adenosine receptor agonists
EP1537133B1 (en) Partial and full agonists of a1 adenosine receptors
EP1789431A1 (en) Partial and full agonists of a1 adenosine receptors
KR20070032007A (ko) A1 아데노신 수용체 아고니스트의 제조 방법

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050215

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080814

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101005

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110622

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20101005

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I